Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302) - 15/10/18
, Stuart D. Shanler, MD, FAAD, FACMS jAbstract |
Background |
Approved topical treatments for seborrheic keratoses (SKs) are an unmet need.
Objective |
To evaluate the safety and efficacy of 40% hydrogen peroxide topical solution (HP40) versus vehicle for the treatment of SKs (A-101-SEBK).
Methods |
A total of 937 patients with 4 SKs each (≥1 lesion each on the face and on the trunk and/or an extremity) were randomized 1:1 to HP40 or vehicle. At each visit, SKs were graded using the Physician's Lesion Assessment (PLA) scale (0, clear; 1, nearly clear; 2, ≤1 mm thick; and 3, >1 mm thick). After 1 treatment, SKs with a PLA score higher than 0 were re-treated 3 weeks later.
Results |
At day 106, significantly more patients treated with HP40 than with vehicle achieved a PLA score of 0 on all 4 SKs (study 1, 4% vs 0%; study 2, 8% vs 0% [both P < .01]) and on 3 of 4 SKs (study 1, 13% vs 0%; study 2, 23% vs 0% [both P < .0001]). A higher mean per-patient percentage of SKs were clear (study 1, 25% vs 2%; study 2, 34% vs 1%) and clear or nearly clear (study 1, 47% vs 10%; study 2, 54% vs 5%) with HP40 than with vehicle. Local skin reactions were largely mild and resolved by day 106.
Limitations |
The optimal number of treatment sessions was not evaluated.
Conclusion |
Application of HP40 was well tolerated and effective in the removal of SKs.
Le texte complet de cet article est disponible en PDF.Key words : A-101, HP40, hydrogen peroxide, local skin reactions, Physician's Lesion Assessment score, seborrheic keratosis, topical solution
Abbreviations used : AE, HP, HP40, LSR, PLA, PP, SAE, SK, TEAE
Plan
| Funding source: Supported by Aclaris Therapeutics Inc. |
|
| Disclosure: Dr Baumann is a scientific advisor and clinical study investigator for Aclaris Therapeutics, Inc. Dr Draelos has received study grants from Aclaris. Dr Lupo, Dr Smith, and Dr Wilson are clinical study investigators for Aclaris. Dr Schlessinger is a stockholder of Aclaris. Dr Bradshaw has received fees from Aclaris for statistical consulting and analysis and is a stockholder of the company. Dr Estes and Dr Shanler are employees of Aclaris. Dr Kempers has no conflicts of interest to disclose. |
Vol 79 - N° 5
P. 869-877 - novembre 2018 Retour au numéro
Article précédent
- Ablative fractional laser–assisted photodynamic therapy provides superior long-term efficacy compared with standard methyl aminolevulinate photodynamic therapy for lower extremity Bowen disease
- Ho-Jin Kim, Ki-Hoon Song
- Folliculitis decalvans: Effectiveness of therapies and prognostic factors in a multicenter series of 60 patients with long-term follow-up
- Laura Miguel-Gómez, Ana R. Rodrigues-Barata, Ana Molina-Ruiz, Antonio Martorell-Calatayud, Pablo Fernández-Crehuet, Ramón Grimalt, Didac Barco, Salvador Arias-Santiago, Cristina Serrano-Falcón, Francisco M. Camacho, David Saceda-Corralo, Pedro Jaén-Olasolo, Sergio Vañó-Galván
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?